Madrigal Pharmaceuticals

Breakthrough in Liver Disease Treatments: Madrigal’s Resmetirom Aims to Be the First Approved NASH Therapy

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) recently took a significant stride towards introducing the first treatment for Nonalcoholic Steatohepatitis (NASH) with liver fibrosis. The drug, resmetirom, has cleared a …

Breakthrough in Liver Disease Treatments: Madrigal’s Resmetirom Aims to Be the First Approved NASH Therapy Read More


VESTECK

VESTECK’s “SUTURE-TIGHT” Catheter Technology Takes Center Stage at ISET Meeting

WEST CHESTER, PA — VESTECK, Inc.’s revolutionary “SUTURE-TIGHT”â„¢ catheter technology was spotlighted at the prestigious International Symposium on Endovascular Therapy (ISET) meeting held in Miami, FL, on January 24, 2024.

VESTECK’s “SUTURE-TIGHT” Catheter Technology Takes Center Stage at ISET Meeting Read More
NRx Pharmaceuticals

NRx Pharmaceuticals Completes Enrollment in Pivotal Trial for Suicidal Bipolar Depression Treatment

RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a Pennsylvania-based biopharmaceutical company, recently announced it has completed enrollment for its Phase 2b/3 study of NRX-101. This patented combination of D-cycloserine, …

NRx Pharmaceuticals Completes Enrollment in Pivotal Trial for Suicidal Bipolar Depression Treatment Read More